Donanemab (Kisunla) Infusion Protocol
Administer donanemab as a 30-minute IV infusion every 4 weeks using a graduated dosing schedule: 350 mg (infusion 1), 700 mg (infusion 2), 1,050 mg (infusion 3), and 1,400 mg (infusion 4 and beyond), with mandatory MRI surveillance prior to infusions 2,3,4, and 7 to monitor for ARIA. 1
Dosing Schedule
The FDA-approved protocol uses a titrated approach:
- Infusion 1: 350 mg
- Infusion 2: 700 mg
- Infusion 3: 1,050 mg
- Infusion 4 and beyond: 1,400 mg
Each infusion is administered over approximately 30 minutes every 4 weeks 1. Recent evidence suggests this graduated titration significantly reduces ARIA-E risk (13.7% vs 23.7% with standard dosing) while maintaining comparable amyloid reduction 2.
If an infusion is missed, resume at the same dose as soon as possible, maintaining the 4-week interval 1.
Preparation and Administration
Dilution requirements:
- Dilute with 0.9% sodium chloride injection only
- Final concentration: 4-10 mg/mL
- Allow vials to reach room temperature before preparation
- Inspect for particulate matter (solution should be clear to opalescent, colorless to slightly yellow/brown) 1
Infusion specifics:
- Administer over 30 minutes via IV infusion
- Use aseptic technique throughout preparation 1
MRI Monitoring Schedule
Baseline MRI: Obtain within 12 months prior to treatment initiation 1, 3
Surveillance MRIs required:
- Prior to infusion 2 (week 4)
- Prior to infusion 3 (week 8)
- Prior to infusion 4 (week 12)
- Prior to infusion 7 (week 24) 1, 3
Additional monitoring: Consider MRI prior to the 12th dose in higher-risk individuals (APOE ε4 homozygotes, baseline microhemorrhages) 3. Obtain off-protocol MRI immediately if symptoms suggestive of ARIA develop (headache, confusion, visual disturbances, gait difficulties) 1.
ARIA Management
ARIA-E (Edema/Effusions)
Asymptomatic mild ARIA-E: May continue dosing at current schedule 1
Asymptomatic moderate or severe ARIA-E: Suspend dosing until radiographic resolution on MRI and consider follow-up MRI in 2-4 months 1
Symptomatic mild ARIA-E: May continue based on clinical judgment 1
Symptomatic moderate or severe ARIA-E: Suspend dosing until resolution 1
ARIA-H (Microhemorrhages/Hemosiderin)
Asymptomatic mild ARIA-H: Continue dosing 1
Asymptomatic moderate or severe ARIA-H: Suspend dosing until radiographic stabilization 1
Any symptomatic ARIA-H: Suspend dosing until stabilization and symptom resolution 1
Intracerebral hemorrhage >1 cm: Suspend dosing; use clinical judgment regarding continuation vs permanent discontinuation after stabilization 1
Most ARIA-E occurs by the third infusion (approximately month 3) in 58.3% of affected patients 4. Symptoms typically include headache and confusional state 4.
Pre-Treatment Requirements
Mandatory assessments:
- Confirm amyloid-β pathology by PET or CSF 1, 3
- APOE ε4 genotyping (to stratify ARIA risk) 1, 3
- Baseline MRI within 12 months 1, 3
Exclusion criteria:
4 cerebral microbleeds on baseline MRI
- Cortical superficial siderosis
- Major vascular contribution to cognitive impairment 3
Patient eligibility:
- Mild cognitive impairment or mild dementia (Clinical Stages 3-4)
- MMSE 20-30
- Biomarker-confirmed AD pathology 1, 3
APOE ε4 Risk Stratification
APOE ε4 status is the strongest predictor of ARIA-E risk:
- ε4/ε4 homozygotes: 33% ARIA-E risk
- ε4 heterozygotes: 7.1% ARIA-E risk
- Non-carriers: 4.3% ARIA-E risk 5, 4
Testing should be performed before treatment initiation, with thorough discussion of implications. Treatment can proceed without genotyping, but ARIA risk cannot be stratified 1.
Treatment Discontinuation
Consider stopping donanemab when:
- Amyloid plaques reduced to minimal levels on PET imaging
- Typically assessed at 12-18 months after treatment initiation 1, 3
In clinical trials, dosing was stopped based on predefined amyloid reduction thresholds on PET 1, 6.
Critical Safety Considerations
Common pitfalls:
- Failing to obtain pre-treatment MRI or APOE genotyping
- Missing scheduled surveillance MRIs (particularly before infusions 2-4 when ARIA-E risk peaks)
- Not recognizing subtle ARIA symptoms (transient confusion, mild headache)
- Continuing treatment with moderate/severe ARIA-E
The graduated dosing schedule is essential—starting at full dose increases ARIA-E risk substantially 2. Most ARIA-E cases in early trials occurred in higher dose groups 5.